CIBC Asset Management Inc Has $360,000 Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

CIBC Asset Management Inc lowered its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 83.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,938 shares of the company's stock after selling 79,321 shares during the period. CIBC Asset Management Inc's holdings in 10x Genomics were worth $360,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. KBC Group NV raised its holdings in 10x Genomics by 38.8% during the 3rd quarter. KBC Group NV now owns 3,225 shares of the company's stock valued at $73,000 after buying an additional 902 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of 10x Genomics by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company's stock worth $143,907,000 after buying an additional 230,145 shares during the period. Venturi Wealth Management LLC grew its position in 10x Genomics by 1,108.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company's stock valued at $55,000 after purchasing an additional 2,240 shares during the last quarter. State of New Jersey Common Pension Fund D grew its position in 10x Genomics by 3.4% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 86,999 shares of the company's stock valued at $1,964,000 after purchasing an additional 2,881 shares during the last quarter. Finally, Axxcess Wealth Management LLC grew its position in 10x Genomics by 38.5% during the 3rd quarter. Axxcess Wealth Management LLC now owns 15,318 shares of the company's stock valued at $346,000 after purchasing an additional 4,258 shares during the last quarter. Institutional investors own 84.68% of the company's stock.

10x Genomics Price Performance

Shares of NASDAQ TXG traded up $1.17 during mid-day trading on Friday, hitting $14.46. The company had a trading volume of 1,859,760 shares, compared to its average volume of 1,728,347. The firm's 50 day simple moving average is $17.73 and its two-hundred day simple moving average is $20.06. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -9.31 and a beta of 1.87. 10x Genomics, Inc. has a 12 month low of $12.95 and a 12 month high of $57.90.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.04. The business had revenue of $151.65 million for the quarter, compared to analysts' expectations of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The company's quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.51) EPS. Equities analysts forecast that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

Analyst Ratings Changes

TXG has been the topic of several recent research reports. Stephens reiterated an "overweight" rating and issued a $30.00 price objective on shares of 10x Genomics in a research note on Thursday, October 10th. Morgan Stanley cut their target price on shares of 10x Genomics from $50.00 to $46.00 and set an "overweight" rating for the company in a report on Tuesday, August 13th. Leerink Partnrs raised shares of 10x Genomics to a "strong-buy" rating in a research note on Tuesday, September 3rd. Citigroup decreased their target price on 10x Genomics from $35.00 to $23.00 and set a "buy" rating for the company in a research report on Wednesday, October 30th. Finally, Canaccord Genuity Group decreased their price objective on 10x Genomics from $32.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, 10x Genomics has an average rating of "Moderate Buy" and a consensus target price of $29.19.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.